
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA showcases a promising outlook due to its innovative pipeline focused on neurodegenerative diseases, particularly with the upcoming EVOKE trial for the NLRP3 program, which could significantly increase interest if outcomes are favorable for Alzheimer's disease patients. Additionally, the company's PD active immunotherapy ACI-7104.056 has demonstrated a remarkable 20-fold increase in antibodies against pathogenic variants of aSyn, indicating strong potential for effective treatment options. Furthermore, the focus on safer delivery methods for monoclonal antibodies through titration dosing enhances the viability of their products, positioning AC Immune favorably in a rapidly evolving treatment landscape for Alzheimer's disease.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, suggesting significant ongoing financial challenges. The company is exposed to inherent risks typical of the biopharmaceutical industry, such as potential adverse clinical results and regulatory hurdles, which could adversely impact its development pipeline. Furthermore, the evolving landscape of commercial markets, characterized by increased price sensitivity, may complicate the successful commercialization of its product candidates.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares